scholarly journals Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis

2007 ◽  
Vol 64 (3) ◽  
pp. 411 ◽  
Author(s):  
Francesco Manfredonia ◽  
Olga Ciccarelli ◽  
Zhaleh Khaleeli ◽  
Daniel J. Tozer ◽  
Jaume Sastre-Garriga ◽  
...  
2018 ◽  
Vol 56 (7) ◽  
pp. 80-84

▼Ocrelizumab (Ocrevus - Roche Registration GmbH) has received marketing authorisation approval from the European Medicines Agency (EMA) for the treatment of adults with multiple sclerosis.1,2 It is the first drug to be licensed for use in early primary progressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, we review the evidence for the safety and effectiveness of ocrelizumab.


Brain ◽  
2005 ◽  
Vol 128 (6) ◽  
pp. 1454-1460 ◽  
Author(s):  
Jaume Sastre-Garriga ◽  
Gordon T. Ingle ◽  
Declan T. Chard ◽  
Mara Cercignani ◽  
Lluís Ramió-Torrentà ◽  
...  

2006 ◽  
Vol 63 (8) ◽  
pp. 1175 ◽  
Author(s):  
Jorge Sepulcre ◽  
Jaume Sastre-Garriga ◽  
Mara Cercignani ◽  
Gordon T. Ingle ◽  
David H. Miller ◽  
...  

NeuroImage ◽  
2007 ◽  
Vol 37 (1) ◽  
pp. 253-261 ◽  
Author(s):  
Z. Khaleeli ◽  
M. Cercignani ◽  
B. Audoin ◽  
O. Ciccarelli ◽  
D.H. Miller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document